Latest Articlesddd

Aerie Pharmaceuticals: Another Step Forward Towards the Approval of a Promising Glaucoma Drug

September 17, 2015 0

Aerie Pharmaceuticals (AERI), which is specialized in glaucoma treatments reported successful results of its second Phase …

Huge Improvement in the Differential Diagnosis of Diseases and More

September 2, 2015 0

The biotechnology industry is proving to be the most innovative and the most growing among Wall …

Why Switzerland Approval of Exelixis and Roche Drug Combination for Melanoma Is a Big Deal

August 27, 2015 0

– The second approval of a cancer drug for Exelixis – The approval of Exelixis/Roche drugs …

A Letter To Prohost Subscribers

August 24, 2015 0

A Letter From Prohost The Stock Market Selloff What’s Going On and What Do We Do …

Seres Therapeutics: A Novel Approach for Treating Clostridium Difficile Infection

August 21, 2015 0

but first: Here is some good news from  SAREPTA Yesterday we wrote about BioMarin (BMRN) being …

Kite: News We Are Anxious to Hear

August 17, 2015 0

Kite Pharma (Kite) stock was sliding, raising concern about the firm and all the biotech firms …

Inovio Is in Much Better Shape Than Six Months Ago

August 13, 2015 0

INOVIO Inovio Pharmaceuticals (INO) is much worth looking at now than 6 months ago. The deal …

Astrazeneca Selects Mirati Therapeutics Drug for Its Cancer Immunotherapy Combination

August 6, 2015 0

In The NEWS IMMUNOTHERAPY MIRATI THERAPEUTICS Mirati Therapeutics (MRTX) is an oncology company focusing on genetic …

NantKwest Inc: A Novel Breathtaking Immunotherapy for Cancer?

August 3, 2015 0

The moment the new IPO NantKwest (NK) landed in the town of publicly traded firms, some …

Prohost Letter #381

July 31, 2015 0

Prohost Letter #381 QUARTERLY FINANCIAL RESULTS IN THE BIOTECH SECTOR Investors Concerns, Excitement and Expectations (Part …

Prohost Letter #380

July 27, 2015 0

Prohost Letter #380 Investors Concerns, Excitments and Expectations PART 2  REGENERON On Friday, July 24, Regeneron …

Exelixis: The Importance of the Public Offering. Xoma: What Should We Do Now?

July 23, 2015 0

Why the financing through a secondary public offering was a must for Exelixis. The outcome of …

Amgen: Repatha Approved in Europe

July 21, 2015 0

The European Commission Approves Amgen’s New Cholesterol-Lowering Medication Repatha™ (evolocumab). The First PCSK9 Inhibitor to Be …

Anacor Pharmaceuticals Ointment for Atopic Dermatitis Passes the Tests. Why Is This Great News?

July 14, 2015 0

An Effective Non-Steroid Atopic Dermatitis Ointment Anacor Pharmaceuticals (ANAC) Announces Positive Top-Line Results From Two Phase …

Prohost Letter #379

July 12, 2015 0

Prohost Letter #379 Investors Concerns, Excitments and Expectations It is understandable the fact that bullish and …

TrovaGene: Overcoming Challenges in Cancer Immunotherapy

July 8, 2015 0

After decades of attempting, but failing, to harness the immune system power to treat cancer (Cancer …

Unearthing Dynavax Treasures Has Nothing to Do with Greece Troubles

June 29, 2015 0

Today it is Greece. What About Tomorrow? Can Greece’s crisis devastate the biotech sector? No sane …

Biocryst: A Major Game Changing Agreement

June 22, 2015 0

On Thursday June 18, 2015, we posted an article under “Today’s Highlights” at the Prohost website …

Prohost Letter #378 Part 2

June 9, 2015 0

Prohost Letter #378 Part 2 2015 ASCO ANNUAL MEETING What a Big Revolution in Oncology! The …

Immunogen: Defeating Advanced Ovarian Cancer and Other Malignancies

June 2, 2015 0

– Immunogen’s recurrent ovarian cancer drug Mirvetuximab soravtansine (IMGN853) has demonstrated promising results. – The firm …